Topical Anti-Inflammatory Treatment of Corneal Neovascularization
Contact Information
Whitney Howe at whitney_howe@meei.harvard.edu
or call (617) 573-5894
Corneal neovascularization is the abnormal growth of blood vessels into the cornea and can put vision at risk. The cornea normally does not contain blood vessels (is avascular), but certain conditions including trauma, infection and inflammation can cause the growth of vessels into the cornea.
Accumulating evidence suggests a significant correlation between the abnormal growth of these blood vessels and the body's inflammatory response.
The purpose of this study is to see if topical anti-inflammatory medication is safe and effective for the treatment of corneal neovascularization. This medication is given in an eye drop and is a synthetic form of a protein that normally occurs in the body.
We are testing whether this medicated eye drop is more effective than an eye drop without medication.
This is a 16 month study consisting of 6 office visits. All patients will receive treatment with both the medicated eye drop and placebo. During each visit photographs of the cornea will be taken.
